Exscientia plc EXAI
Day range unavailable
52-week range unavailable
- Market cap
- 633.18M
- Revenue (ttm)
- 17.07M
- Shares out
- 130.82M
- Forward P/E
- -5.83
- Beta
- 0.83
- Analysts
- Hold
- Price target
- 4.35 (-10.1%)
- Earnings date
- Nov 8, 2024
Key statistics
- Enterprise value
- 407.42M
- PEG ratio
- 0.00
- Price / sales
- 37.10
- Price / book
- 2.48
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -44.50%
- Free cash flow
- -71.97M
- Total cash
- 244.08M
- Total debt
- 18.57M
- Return on equity
- -46.43%
- Short % of float
- 4.30%
- 50-day average
- 5.04
- 200-day average
- 5.26
Analyst view
Consensus: hold
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 8, 2024
Expected Nov 8, 2024. Consensus EPS estimate -0.0961.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2024 | Sep 1, 2024 | -0.30 | — | — | — |
| Aug 15, 2024 | Jun 1, 2024 | -0.31 | — | — | — |
| May 21, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 21, 2024 | Dec 1, 2023 | -0.44 | — | — | — |
| Nov 9, 2023 | Sep 1, 2023 | -0.42 | — | — | — |
| Aug 10, 2023 | Jun 1, 2023 | -0.41 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 13, 2024 | Barclays | down | Overweight | Equal-Weight |
| Aug 9, 2024 | TD Cowen | down | Buy | Hold |
| Jul 29, 2024 | Barclays | main | Overweight | Overweight |
| Jul 9, 2024 | TD Cowen | init | — | Buy |
| Apr 22, 2024 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Jan 5, 2024 | B of A Securities | down | Buy | Neutral |
About Exscientia plc
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- exscientia.ai
News
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session 
Earnings Scheduled For March 21, 2024 
Why IPG Photonics Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Earnings Scheduled For November 9, 2023 
AZZ, VOXX International And Other Big Stocks Moving Higher On Wednesday - Earnings Scheduled For August 10, 2023
- Earnings Scheduled For May 24, 2023
Earnings Scheduled For March 23, 2023 
Stocks That Hit 52-Week Lows On Tuesday
Your note
Sign in to keep a note on EXAI — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Softbank Group Corporation | 4.34% | 5,681,818 | 27.50M | Sep 29, 2024 |
| Laurion Capital Management, LP | 3.42% | 4,473,010 | 21.65M | Sep 29, 2024 |
| Baillie Gifford and Company | 2.94% | 3,848,276 | 18.63M | Sep 29, 2024 |
| Bill & Melinda Gates Foundation | 1.22% | 1,590,909 | 7.70M | Sep 29, 2024 |
| MIC Capital Management UK LLP | 1.18% | 1,542,600 | 7.47M | Sep 29, 2024 |
| Platinum Investment Management Ltd | 1.11% | 1,456,058 | 7.05M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Biotechnology ETF | 0.51% | 670,525 | 3.25M | Sep 29, 2024 |
| WisdomTree Tr-WisdomTree Artificial Intelligence & Innovation Fd | 0.30% | 388,457 | 1.88M | Jun 29, 2024 |
| Themes ETF Tr-Themes Generative Artificial Intelligence ETF | 0.03% | 35,933 | 173.91K | Jun 29, 2024 |
| Baillie Gifford Health Innovation Equities Fund | 0.02% | 28,654 | 138.69K | Jun 29, 2024 |
| SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF | 0.02% | 25,152 | 121.73K | Sep 29, 2024 |
| ETF Series Solutions-Range Cancer Therapeutics ETF | 0.02% | 27,925 | 135.16K | Aug 30, 2024 |